Avian Influenza A Virus
3
1
2
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
6 treatments under study, led by Oseltamivir
Research Leaders
13 sponsors active, led by Canadian Center for Vaccinology
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 3 trials
100.0%
+13.4% vs benchmark
33%
1 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (3)
Safety and Immunogenicity of the Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented and Adjuvanted) in Adults and Older Adults
Immunogenicity and Safety of 2 Doses of Avian Influenza A (H5N1) Vaccine Administered 3 vs. 8 Weeks Apart
Pharmacologic Study of Oseltamivir in Healthy Volunteers
Research Network
Common Treatments
- Oseltamivir1
- Monovalent Influenza Vaccine A H5n8 Inactivated Fragmented And Adjuvanted 75 Mcg1
- Monovalent Influenza Vaccine Type A H5n8 15 Mcg1
- Probenecid1
- Saline As A Placebo1
Active Sponsors
- Canadian Center for Vaccinology1
- Canadian Immunization Research Network1
- Public Health Agency of Canada (PHAC)1
- Dalhousie University1
- National Institute of Allergy and Infectious Diseases (NIAID)1
Top Investigators
CIRN, Canadian Center for Vaccinology, Dalhousie University
Associate Professor, Department of Clinical Tropical Medicine Faculty of Tropical Medicine, Mahidol University
Related Conditions
- Avian Influenza1
- H5n1 Influenza1
- H5n1 Virus1